Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Assembly Biosciences
(NQ:
ASMB
)
14.61
+0.20 (+1.39%)
Streaming Delayed Price
Updated: 3:49 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Assembly Biosciences
< Previous
1
2
3
4
Next >
Why Are Stocks Down Today?
October 17, 2023
Stocks are down today, and investors wondering why are in the right place as we have all the details they need to know about on Tuesday!
Via
InvestorPlace
Why Is Assembly Biosciences (ASMB) Stock Up 92% Today?
October 17, 2023
Assembly Biosciences stock is taking off with heavy trading of ASMB shares after the company announced a new collaboration agreement!
Via
InvestorPlace
Nasdaq Down Over 1%; US Retail Sales Top Expectations
October 17, 2023
U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 1% on Tuesday. Following the market opening Tuesday, the Dow traded down 0.11% to 33,947.98 while the NASDAQ fell...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Hepatitis-Focused Assembly Biosciences Stock Trading Over 100% Higher: Here's Why
October 17, 2023
Gilead Sciences Inc (NASDAQ: GILD) and Assembly Biosciences Inc (NASDAQ: ASMB) have entered into a 12-year partnership.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 17, 2023
Via
Benzinga
Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
October 17, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Assembly Biosciences to Present New Data at AASLD The Liver Meeting®
October 11, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor
October 02, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting
September 19, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports Second Quarter 2023 Financial Results and Recent Updates
August 09, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop
July 17, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
July 14, 2023
Via
Benzinga
Assembly Biosciences Presents New Data Highlighting Entry Inhibitor and Core Inhibitor Programs at EASL’s International Liver Congress™ 2023
June 21, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023
June 07, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference
May 23, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights
May 04, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Announces Additional Promising Data from Phase 1a Clinical Trial Evaluating Highly Potent Next-Generation Core Inhibitor Candidate ABI-4334 and Provides Pipeline Update
April 18, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 03, 2023
Via
Benzinga
Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights
March 22, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Nominates First Herpesvirus Development Candidate ABI-5366, a Long-Acting HSV-2 Helicase Inhibitor Targeting High-Recurrence Genital Herpes
February 15, 2023
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Shares Gain After Promising Early Cut Data From HBV Infection Programs
December 19, 2022
Assembly Biosciences Inc (NASDAQ: ASMB) announced interim efficacy, safety, and pharmacokinetic (PK) results from a Phase 1b study of ABI-H3733 (3733) and a Phase 1a study of ABI-4334 (4334).
Via
Benzinga
Assembly Biosciences Announces Promising Interim Results from Two Clinical Trials Evaluating Highly Potent Next-Generation Core Inhibitor Candidates ABI-H3733 and ABI-4334
December 19, 2022
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Doses First Subject in Phase 1a Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of Investigational Next Generation Core Inhibitor ABI-4334
November 14, 2022
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights and Announces Upcoming Conference Participation
November 08, 2022
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV
November 04, 2022
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
NVIDIA To $140? Plus This Analyst Cuts PT On Assembly Biosciences By 82%
October 24, 2022
Truist Securities cut the price target on Assembly Biosciences, Inc. (NASDAQ: ASMB) from $11 to $2. Assembly Biosciences shares gained 2.6% to trade at $1.58 on Monday.
Via
Benzinga
Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®
October 24, 2022
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A. Okazaki as Successor
October 05, 2022
Dr. McHutchison will continue to provide strategic counsel as board member and chairman of the Science & Technology Committee of the board
From
Assembly Biosciences, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 24, 2022
October 24, 2022
Upgrades
Via
Benzinga
Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
July 21, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.